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C
oronavirus infections historically
were associated with mild upper
respiratory tract diseases in in-
fants, children, and adults.
Human coronavirus (HCoV)-OC43 and
HCoV-229E were associated with 15–30%
of common colds in winter and occasion-
ally linked with lower respiratory tract
disease in populations with chronic under-
lying diseases. HCoV research was com-
plicated by the lack of a reverse genetic
system or animal model. These viruses
propagated poorly, and the number of
reagents was limited. However, coronavi-
ruses are capable of rapid host switching
and evolution in changing ecologies (1),
suggesting that their diversity and role in
human disease were underappreciated.
The 21st century heralded the arrival of
the more pathogenic coronaviruses, like
severe acute respiratory syndrome
(SARS)-CoV. Then, HCoV-NL63 was
identified as an important cause of severe
lower respiratory tract infections in chil-
dren and adults, including a tentative link-
age with Kawasaki disease (2), and
HCoV-HKU1 was identified in adults
with pneumonia (3–5), renewing interest
in the replication mechanisms and patho-
genesis of HCoV-OC43 and HCoV-229E.
In this issue of PNAS, Lassnig et al. (6)
describe a transgenic mouse model to
study HCoV-229E replication and patho-
genesis, laying the groundwork for devel-
oping transgenic mouse models for other
HCoVs.
HCoVs
HCoVs include the group 1 (HCoV-
229E and HCoV-NL63) and group 2
(HCoV-OC43 and HCoV-HKU1) sero-
types (3, 4). The SARS-CoV classifica-
tion is controversial, representing either
the prototype group 4 strain or a distant
relative of the group 2 viruses (5). They
contain a linear single-stranded positive
polarity RNA genome 27–32 kb in
length with the 5-most two-thirds of the
genome encoding two large ORFs that
function in replication (Fig. 1). Struc-
tural genes encode the spike (S) glyco-
protein, a membrane (M) glycoprotein,
the envelope (E) protein, and the nu-
cleocapsid (N) protein. Structural ORFs
are interspaced with accessory ORFs of
unknown function, and all are expressed
from subgenomic mRNAs that are ar-
ranged in the form of a nested set from
the 3 end of the genome (7). The S
glycoprotein interacts with the receptor
and is a critical determinant of host
range, cross-species transmission, and
pathogenesis (1). HCoV-OC43 and
HKU1 also encode a hemagglutinin ester-
ase whose function in replication is un-
known. HCoVs use several host proteins
for docking and entry, including amino-
peptidase N (hAPN, HCV 229E), angio-
tensin-converting enzyme 2 (SARS-CoV),
and neuraminic acid (HCoV-OC43)
(8–10). Entry is a primary obstacle for
initiating productive infection of cells in
vitro and in vivo, although other sites of
virus–host interaction likely contribute
as well.
Fundamental barriers to HCoV re-
search were the development of reverse
genetic systems and robust animal mod-
els. Genetic obstacles were obliterated
by Thiel et al. (11), who developed the
first molecular clone for a HCoV,
HCoV-229E, after inserting a full-length
genome copy into a poxvirus vector to
drive full-length infectious transcripts.
Shortly thereafter, Yount et al. (12)
isolated a molecular clone of the SARS-
CoV by cloning the genome as six
fragments that could be systematically
assembled into a full-length cDNA in
vitro and serve as the genomic template
for the recovery of infectious transcripts
(12). Using genetic approaches, the role
of the accessory genes in coronavirus
pathogenesis has been studied, foreign
genes have been expressed, and corona-
virus replicon particles have been
developed as delivery vehicles for heter-
ologous vaccines and therapeutics (13).
Animal Models of Human Disease
The receptor for HCoV-229E, hAPN, also
termed CD13, is a 150-kDa membrane-
bound exopeptidase, which is constitu-
tively expressed and forms dimers on the
surface of a wide variety of cells (10).
APN functions in digestion, angiogenesis,
and synaptic activity and cleaves peptides
bound to MHC molecules of antigen-
presenting cells. Transfection of nonper-
missive cells with hAPN is sufficient to
confer susceptibility to HCoV-229E infec-
tion (10). For the group 1 coronaviruses,
early attempts at developing transgenic
mice expressing the hAPN receptor failed
to produce a susceptible model, suggesting
that other cofactors might be essential for
in vivo replication (14). This outcome is
not unique to HCoV-229E; similar find-
ings were reported in transgenic mice ex-
pressing the poliovirus and measles virus
receptors (15). Although the fundamental
basis for this dichotomy remains undeter-
mined, modifications that enhanced virus
growth in these models included the gen-
eration of double-transgenic mice that
See companion article on page 8275.
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Fig. 1. Schematic of HCoV genomes. Schematic diagrams are shown for each HCoV. White rectangles and
dark gray squares represent the leader transcription regulatory sequence and leader sequence, respec-
tively. Color coding indicates hemagglutinin esterase (HE; green), spike (S; pink), envelope (E; orange),
membrane (M; blue), nucleocapsid (N; yellow), accessory ORFs (gray).
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also contained defects in innate immune
responses, virus strain variation, or
changes in the route of inoculation.
Lassnig et al. (6) resolved issues with
the hAPN transgenic mice by using a
comprehensive APN regulatory element,
which allowed for near equivalent levels
of hAPN expression in the appropriate
organs with that seen by endogenous
APN levels. Unfortunately, although the
primary embryo fibroblasts (PEFs) from
the transgenic mice were susceptible to
infection by HCoV-229E, the animals
were not productively infected with virus.
To increase HCoV-229E replication,
double-transgenic mice were obtained by
crossing the hAPN homozygous males to
immunocompromised Stat1/ females,
which have impaired innate immune re-
sponses. PEF cultures from the double-
transgenic mice were robust hosts for
HCoV-229E replication, but, again, virus
failed to infect the hAPN/Stat1/
mice. Like other RNA viruses that have
narrow host ranges, coronaviruses evolve
quickly after blind serial passage either
in vitro or in vivo and can rapidly be
adapted to new host species (1). Refusing
to be deterred, Lassnig et al. passaged
WT HCoV-229E four times in PEF
cultures from hAPN/Stat/ mice,
selecting a variant HCoV-229E-37 that
replicated more efficiently in this genetic
background and in cultures derived from
hAPN/Stat/ mice. Consistent with
the role of the S glycoprotein gene in in-
fluencing host range and pathogenesis,
two amino acid changes (T278I and N814A)
were noted in S1. Although these muta-
tions flank the principal hAPN receptor
binding domain located between amino
acids 407 and 547 in the HCoV-229E S
(16), their functional significance is un-
known. These mutations may mitigate
functions associated with entry or release
or encode residues that interact with mu-
rine coreceptor molecules critical for in
vivo infection. Previous studies have indi-
cated that other group I coronavirus S
glycoproteins might interact with sialic
acid (17), and dendritic cell-specific intra-
cellular adhesion molecule 3 grabbing
nonintegrin and CD209L may function
as coreceptors for SARS-CoV docking
and entry into particular cell types (18).
Similar in vitro passages have enhanced
rhinovirus replication in murine cells har-
boring the human intercellular adhesion
molecule-1 receptor (19).
Importantly, HCoV-229E-37 replicated
efficiently in hAPN/Stat/ mice but
not in hAPN/ or Stat/ control ani-
mals after inoculation through oral,
intranasal, intragastric, and i.p. routes si-
multaneously or via the nasal route only.
Virus was detected in large amounts in
the lungs and the gut after multiple
route challenge and in the lungs after
intranasal challenge. Clinically, animals
showed a mild weight loss, slight tem-
perature increases, and hemorrhagic ar-
eas in the lungs and small intestine. An-
imals inoculated via the intranasal route
also displayed histopathology in the lung
consistent with active virus replication.
Future Directions
Lassnig et al.’s article (6) provides a para-
digm for the generation of transgenic
animals that are susceptible to HCoVs.
SARS-CoV replicates efficiently in
BALBc mice without significant clinical
disease or pathology, limiting the useful-
ness of this model for viral pathogenesis
studies and the identification of virulence
determinants (20). The development of
human angiotensin-converting enzyme 2
transgenic animals may well serve as a
more robust model for SARS-CoV. Im-
portantly, hAPN humanized mice allow
studies into HCoV-229E pathogenesis,
tropism, replication, and spread in an im-
munocompromised host. hAPN is highly
polymorphic in human populations, and
the availability of this animal model al-
lows investigation into whether allelic
variation in the receptor influences
HCoV-229E replication and pathogenesis
in vivo, as has been so elegantly described
for other RNA viruses like noroviruses
(21, 22). The molecular basis for HCoV-
229E adaptation represents another rich
avenue of investigation. Although the S
glycoprotein may be critical, other genetic
changes could equally contribute to in vivo
replication, adaptation, and pathogenesis.
Because virus entry and spread are often-
times restricted by innate host defense
mechanisms, it is likely that one or more
mutations may evolve that restrict activa-
tion of antiviral host genes in Stat/
mice. The molecular clone for HCoV-
229E provides the necessary tool for the
identification and functional analysis of
genetic elements responsible for in vivo
adaptation and pathogenesis.
Murine models for HCoV-229E and
SARS-CoV infection provide a means to
study viral vector tropism and the efficacy
and biosafety of HCoV-based vaccine vec-
tors. The coronaviruses’ unique genome
organization and replication strategy allow
simultaneous regulated expression of mul-
tiple foreign genes from transcription reg-
ulatory sequences encoded at the 3 end
of the genome. Coronavirus vectors can
be targeted to different species, tissues,
and mucosal compartments allowing for
directed gene expression. It is likely that
several kilobases of foreign genetic mate-
rial can be stably incorporated and ex-
pressed in coronavirus genomes. HCoV
vectors can be designed to safely target
payloads to specific tissues or organs (13).
The achievement by Lassnig et al. (6) will
encourage further studies into human
coronavirus replication and pathogenesis
in vivo while simultaneously propelling the
development of second-generation animal
models for applying coronavirus-based
vaccines and therapeutics in the treatment
of human diseases.
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